IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update

Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of December 31, 2022 is anticipated to fund planned operations into...

Related Keywords

Sydney ,New South Wales ,Australia ,United Kingdom ,Melbourne ,Victoria ,Manchester ,Russia ,Ukraine ,Darrinm Beaupre ,Yujiros Hata ,Werner Helicase ,Michael White ,Amgen ,University Of Manchester ,Nasdaq ,Novartis ,Exchange Commission ,Biosciences Inc ,Pfizer ,Cancer Research United Kingdom ,Alfred Health ,Program Updates ,Pol Theta Helicase ,Chief Executive Officer ,Senior Vice President ,Chief Medical Officer ,Chief Scientific Officer ,Non Small Cell Lung Cancer ,Oesophagogastric Cancer ,Amgen Sponsored Phase ,Amgen Clinical Trial Collaboration ,Supply Agreement ,Crizotinib Combination Therapy ,Metastatic Uveal Melanoma ,Disease Control Rate ,Overall Response Rate ,Tumor Reduction ,Study Follow Up ,Progression Free Survival ,Fast Track ,New Drug Application ,Orphan Drug ,Uveal Melanoma ,Adjuvant Uveal Melanoma ,Royal Victorian Eye ,Ear Hospital ,Clinical Trial Collaboration ,Pol Theta ,Pol Theta Helicase Inhibitor ,Investor Relations ,Vice President ,Chief Financial Officer ,Ideaya Biosciences ,Nc ,